intravenous glutathione randomized controlled trial parkinson's disease Revamping therapy using PLGA-based drug delivery systems Targeting Ferroptosis in Parkinson's Disease:

Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S

LOX-1 signaling also activates arginase II, further antagonizing NO formation by competing with eNOS for its substrate L-arginine ( Associations between cardiovascular risk factors and changes to the hemodynamic environment of the endothelium are less clearly defined, however there is evidence to suggest that many cardiac comorbidities influence the capacity of the endothelium to respond to shear stresses, likely due in part to phenotypic disruptions caused by inflammatory activation and oxidative stress

Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis

Properties: Cinnamaldehyde, Trans-cinnamaldehyde